301267 华厦眼科
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入3,341,3492.13%4,139,1634,027,0114,013,1643,233,246
减:营业总成本2,755,3462.05%3,566,6723,453,8763,144,2142,538,435
    其中:营业成本1,850,9832.92%2,346,5602,247,3472,045,4241,679,725
               财务费用36,9919.34%47,48335,06520,00831,696
               资产减值损失(1,032)-34.29%(7,822)(14,220)(5,552)(727)
公允价值变动收益25,678478.13%(9,294)(5,087)11,0216,512
投资收益10,317-67.14%46,59770,84976,4387,993
    其中:对联营企业和合营企业的投资收益(13,825)353.66%(6,013)------
营业利润644,7294.86%615,595644,451973,397727,448
利润总额635,5069.57%573,812563,170854,313653,613
减:所得税费用142,03314.61%140,756134,955176,893144,415
净利润493,4738.20%433,056428,215677,420509,199
减:非控股权益27,32921.90%(7,598)(425)11,488(4,623)
股东净利润466,1447.49%440,654428,641665,932513,821

市场价值指针
每股收益 (元) *0.5505.77%0.5300.5100.7900.670
每股派息 (元) *0.10011.11%0.2600.2200.1100.280
每股净资产 (元) *6.660-6.74%6.2746.8986.7329.132
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容